H.R. 6283 118th Congress
DRUG Act
Latest action, Dec 17, 2024: Referred to the Subcommittee on Health.
How the House voted
The House hasn't taken a roll call on this bill in the Congresses covered.
25 cosponsors
Sponsored by Mariannette Miller-Meeks (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
10 D · 15 R
- Democrat
- Republican
- Independent
Referred to: House: Education and Workforce Committee; House: Energy and Commerce Committee; House: Oversight and Government Reform Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
BRISTOL-MYERS SQUIBB
CROSSROADS STRATEGIES, LLC
5 reports
5 reports
FRESENIUS KABI USA LLC
WEST FRONT STRATEGIES LLC
5 reports
5 reports
5 reports
5 reports
MERCK & CO., INC.
CROSSROADS STRATEGIES, LLC
5 reports
5 reports
5 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
YC CONSULTING, LLC
5 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
CROSSROADS STRATEGIES, LLC
5 reports
The top 25 of 59 clients, by reports
| Client | Lobbying firm | Reports | Reports totaling | From | To | House |
|---|---|---|---|---|---|---|
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 5 | $14.2M | Q4 2023 | Q3 2024 | yes | |
| BRISTOL-MYERS SQUIBB | CROSSROADS STRATEGIES, LLC | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| ELEVANCE HEALTH, INC. | 5 | $7.6M | Q4 2023 | Q3 2024 | yes | |
| FRESENIUS KABI USA LLC | WEST FRONT STRATEGIES LLC | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| GSK (FKA GLAXOSMITHKLINE INC.) | 5 | $6.3M | Q4 2023 | Q3 2024 | yes | |
| HEALTHCARE INSTITUTE OF NEW JERSEY | 5 | $274K | Q4 2023 | Q3 2024 | yes | |
| MERCK & CO INC | 5 | $11.1M | Q4 2023 | Q3 2024 | yes | |
| MERCK & CO., INC. | CROSSROADS STRATEGIES, LLC | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 5 | $1.8M | Q4 2023 | Q3 2024 | yes | |
| NATIONAL RURAL LETTER CARRIERS' ASSOCIATION | 5 | $567K | Q4 2023 | Q3 2024 | yes | |
| NATIONAL TREASURY EMPLOYEES UNION | 5 | $1.5M | Q4 2023 | Q3 2024 | yes | |
| NOVARTIS | 5 | $6.9M | Q4 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | YC CONSULTING, LLC | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 5 | $37.4M | Q4 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | CROSSROADS STRATEGIES, LLC | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | OGR | 5 | $250K | Q4 2023 | Q3 2024 | yes |
| SANOFI US SERVICES INC. | CROSSROADS STRATEGIES, LLC | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| TAKEDA PHARMACEUTICALS AMERICA INC | 5 | $3.4M | Q4 2023 | Q3 2024 | yes | |
| TAKEDA PHARMACEUTICALS AMERICA, INC. | CROSSROADS STRATEGIES, LLC | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | 5 | $10.2M | Q4 2023 | Q3 2024 | yes | |
| AMERICAN PHARMACY COOPERATIVE, INC. | ARENTFOX SCHIFF LLP | 4 | $120K | Q1 2024 | Q3 2024 | yes |
| AMGEN | THE MCMANUS GROUP | 4 | $0 | Q4 2023 | Q3 2024 | yes |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 4 | $6.7M | Q1 2024 | Q3 2024 | yes | |
| CVS HEALTH (AND SUBSIDIARIES) | 4 | $9.2M | Q1 2024 | Q3 2024 | yes | |
| EMD SERONO, INC. | THE MCMANUS GROUP | 4 | $0 | Q4 2023 | Q3 2024 | yes |